Stockreport

Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]

Sarepta Therapeutics, Inc.  (SRPT) 
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF Sarepta Therapeutics (NasdaqGS:SRPT) reported positive three year functional results from its Phase 3 EMBARK trial of Elevidys in ambulatory Duchenne muscular dystrophy [Read more]